MO

Moleculin Biotech, Inc.

publicNasdaq: MBRXsec discovery
· Pharmaceutical Preparations· HOUSTONCIK 0001659617 ↗
Compare
Scores 2 h agoLast event 4 d agoSTALE · SEC 4 d ago
Radar composite
23.7+14.7over 30 days
ACCELERATING+22.3
Last signal
Active signals
50 of 65
Confidence
77%

Signal score, not a calibrated probability · config v1 · scores

Contributing dimensions

SCORE BREAKDOWN

IPO
47.5
Readiness 65 · structural
Tokenization
0.0
Securities-tokenization evidence
On-chain
0.0
Settlement / custody infrastructure
Explainable scoring

Why it scores this way

Methodology →

Raising the score

decayed points
  • IPO+13.4 points added to the score
    Filing Evidence
    13 signals after decay · component at 67/100, weighted 20% of the dimension
  • IPO+11.4 points added to the score
    Regulatory Evidence
    51 signals after decay · component at 71/100, weighted 16% of the dimension
  • IPO+8.0 points added to the score
    Financial Maturity
    company is already public
  • IPO+8.0 points added to the score
    Funding Maturity
    total funding $6M, latest round series_e (late stage +25)
  • IPO+4.0 points added to the score
    Market Conditions
    201 S-1/F-1 filings on EDGAR in last 90d vs baseline 60
  • IPO+2.5 points added to the score
    Recency
    most recent supporting signal 23d old (recency factor 0.84)
  • IPO+0.1 points added to the score
    Recent Capital Activity
    1 signal after decay · component at 1/100, weighted 6% of the dimension

Holding it back

No contradicting evidence, and nothing has decayed materially yet.

Points are shown after time decay and source-quality weighting. Evidence loses weight on a half-life of IPO 90d · TOK 120d · CHAIN 180d and is dropped entirely after 730 days. Scoring configuration v1. This is a signal score, not a calibrated probability.

Showing component-level attribution. Which individual filing or article moved each component — and the day-over-day change explanation — is part of Pro. Compare plans →

Score movement

What changed

7 daily snapshots
8.423.7+15.3radar composite over 10 days
Last 10 days
+15.38.4 → 23.7
Last 24 days
+14.98.8 → 23.7

Evidence detected in the last 7 days

  • Other SEC filing+0.2

    424B5 filed by Moleculin Biotech, Inc. — FORM 424B5

    OfficialSEC EDGAR

These are scored events the pipeline retrieved inside the window. A move is not only new evidence: existing signals also lose weight to time decay, corroboration can change, and company attributes such as funding or status can move a component. This list is limited by your plan, so there may be more.

ProHow much of the move was each factor

The windows and the evidence above are the whole free picture: what moved, and what arrived. Pro decomposes the move itself into new evidence, decay, corroboration and attribute changes, per dimension.

  • Points from new evidence versus points lost to decay
  • Corroboration and source-quality changes, separated
  • Attribute changes: funding, valuation, status
  • Any two dates, not just the fixed windows
Upgrade to Pro
Score history

Trend

7 daily snapshots
02550751002026-08-192026-09-082026-09-12
Radar IPO Token On-chain
Comparable companies
Companies comparable to Moleculin Biotech, Inc.
CompanyIPOTokenOn-chainMomentum
Veradermics, Inc4800
Aptevo Therapeutics Inc.4300
HCW Biologics Inc.5300
Sunshine Biopharma Inc.4200
Optimi Health Corp.4000
Onconetix, Inc.3900
Side-by-side comparison →
Company overview

PROFILE

Founded
not on record
Employees
not on record
Latest valuation
none on record
Latest round
Series E $6M (2025-06-20)
Total funding
$6M
Major investors
none on record
Executives
none on record
Aliases
Moleculin Biotech, Inc.
Funding history (extracted)
IPO status

IPO SIGNAL SCORE

Signal score
47.5 signal score — not a calibrated probability
IPO readiness
65.0 structural (maturity, funding, valuation)
Timeline estimate
prediction already public
Filing status
fact PUBLIC
Public/private
public
Known banks
none detected
Advisors
none detected
Score components
  • Filing Evidence13.4 / 20.0 pts
    13 signals · 13 decayed signal(s), mass 61.4 → 67.3/100 (k=55) × weight 0.2
  • Regulatory Evidence11.4 / 16.0 pts
    51 signals · 51 decayed signal(s), mass 74.7 → 71.2/100 (k=60) × weight 0.16
  • Financial Maturity8.0 / 8.0 pts
    Company attribute · company is already public
  • Funding Maturity8.0 / 8.0 pts
    Company attribute · total funding $6M, latest round series_e (late stage +25)
  • Market Conditions4.0 / 4.0 pts
    Company attribute · 201 S-1/F-1 filings on EDGAR in last 90d vs baseline 60
  • Recency2.5 / 3.0 pts
    Company attribute · most recent supporting signal 23d old (recency factor 0.84)
  • Recent Capital Activity0.1 / 6.0 pts
    1 signal · decayed funding/valuation signal mass 2.2 → +0.1 pts (cap 6)
  • Liquidity Evidence0.0 / 6.0 pts
    Company attribute · no signals in window
  • Valuation Maturity0.0 / 8.0 pts
    Company attribute · no valuation on record
  • Banking Evidence0.0 / 14.0 pts
    Company attribute · no signals in window
  • Corporate Restructuring0.0 / 5.0 pts
    Company attribute · no signals in window
  • Executive Evidence0.0 / 8.0 pts
    Company attribute · no signals in window

47.5 points total, out of 100 available at these weights.

Recent IPO / regulatory / banking evidence
  • Other SEC filing+0.2

    424B5 filed by Moleculin Biotech, Inc. — FORM 424B5

    OfficialSEC EDGAR
Tokenization status

TOKENIZATION SIGNAL SCORE

Signal score
0.0
On-chain readiness
0.0
Tokenization partners
none detected
Custody
none detected
Transfer agent
none detected
Exchanges / venues
none detected
Settlement
none detected
Blockchains
none detected
Score components
  • Regulatory Readiness0.0 / 8.0 pts
    Company attribute · no signals in window
  • Recency0.0 / 4.0 pts
    Company attribute · no recent signals
  • Explicit Statements0.0 / 18.0 pts
    Company attribute · no signals in window
  • Executive Statements0.0 / 8.0 pts
    Company attribute · no signals in window
  • Custody Infrastructure0.0 / 7.0 pts
    Company attribute · no signals in window
  • Exchange Relationships0.0 / 8.0 pts
    Company attribute · no signals in window
  • Blockchain Partnerships0.0 / 10.0 pts
    Company attribute · no signals in window
  • Securities Infrastructure0.0 / 12.0 pts
    Company attribute · no signals in window
  • Settlement Infrastructure0.0 / 8.0 pts
    Company attribute · no signals in window
  • Tokenization Partnerships0.0 / 17.0 pts
    Company attribute · no signals in window

0.0 points total, out of 100 available at these weights.

On-chain readiness components
  • Custody0.0 / 12.0 pts
    Company attribute · no signals in window
  • Settlement0.0 / 12.0 pts
    Company attribute · no signals in window
  • Kyc Aml Readiness0.0 / 10.0 pts
    Company attribute · no signals in window
  • Tokenization Provider0.0 / 14.0 pts
    Company attribute · no signals in window
  • Blockchain Integration0.0 / 12.0 pts
    Company attribute · no signals in window
  • Transfer Infrastructure0.0 / 12.0 pts
    Company attribute · no signals in window
  • Regulatory Compatibility0.0 / 12.0 pts
    Company attribute · no signals in window
  • Securities Infrastructure0.0 / 16.0 pts
    Company attribute · no signals in window

0.0 points total, out of 100 available at these weights.

Tokenization / blockchain evidence

No evidence of this kind on record.

IPO Radar is a research and intelligence tool. Scores are signal scores derived from public evidence — they are not calibrated probabilities and not investment advice. FACT, INFERENCE and PREDICTION are kept separate, and every event links to its source.